<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01491620</url>
  </required_header>
  <id_info>
    <org_study_id>C-11-XPC01</org_study_id>
    <nct_id>NCT01491620</nct_id>
  </id_info>
  <brief_title>Study of the 532 nm KTP Laser for the Treatment of Poikiloderma of Civatte</brief_title>
  <official_title>A Single-Center Prospective, Open-Label Study of the Excel V 532 nm KTP Laser for the Treatment of Poikiloderma of Civatte</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cutera Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cutera Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of the Excel V 532 nm KTP laser for the
      treatment of dyschromia of the neck and/or chest (poikiloderma of Civatte).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severity Assessment Score</measure>
    <time_frame>24 weeks post final treatment</time_frame>
    <description>Change in physician's Severity Assessment score based on blinded assessment of subject photographs by a panel of independent dermatologists.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physician's Global Assessment (Blinded)</measure>
    <time_frame>24 weeks post final treatment</time_frame>
    <description>Before and after subject photographs will be presented to a panel of independent dermatologists. The panel will be blinded to treatment parameters and the photograph time point. Each dermatologist will be asked to select the baseline photograph and then rate improvement in poikiloderma of Civatte in the post-treatment photograph using a 5-point improvement scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physician's Global Assessment</measure>
    <time_frame>12 and 24 weeks post final treatment</time_frame>
    <description>Investigator will assess improvement in poikiloderma of Civatte as compared to baseline using a 5-point improvement scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity Assessment Score</measure>
    <time_frame>12 and 24 weeks post final treatment</time_frame>
    <description>Investigator will perform Severity Assessment of the subject's poikiloderma of Civatte.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's Global Assessment</measure>
    <time_frame>12 and 24 weeks post final treatment</time_frame>
    <description>Subjects will assess improvement of poikiloderma of Civatte as compared to baseline using a 5-point improvement scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Satisfaction Assessment</measure>
    <time_frame>12 and 24 weeks post final laser treatment</time_frame>
    <description>Subjects will assess overall satisfacion with improvement of poikiloderma of Civatte and proceedure using a 5-point satisfaction scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spectrophotometer Measurement</measure>
    <time_frame>12 and 24 weeks post final laser treatment</time_frame>
    <description>Change in pigmentation and erythema as assessed by spectrophotometer measurements as compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Adverse Events</measure>
    <time_frame>24 weeks post final laster treatment</time_frame>
    <description>Incidence and severity of all procedure-related adverse events.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Poikiloderma of Civatte</condition>
  <condition>Dyschromia</condition>
  <condition>Pigmentation Disorders</condition>
  <condition>Telangiectasia</condition>
  <condition>Photosensitivity Disorders</condition>
  <arm_group>
    <arm_group_label>532 nm KTP laser treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>532 nm KTP laser</intervention_name>
    <description>Two laser treatment sessions, 6 weeks apart.</description>
    <arm_group_label>532 nm KTP laser treatment</arm_group_label>
    <other_name>Excel V</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fitzpatrick Skin Type I - III

          -  Clinical diagnosis of poikiloderma of Civatte affecting the neck and/or chest

          -  Willing to refrain from using topical corticosteroids, retinoids and bleaching agents
             on the treated area

          -  Agree not to undergo any other procedure for the treatment of poikiloderma of Civatte
             during the study

          -  Willing and able to read, understand and sign the Informed Consent Form

          -  Willing and able to adhere to the treatment and follow-up schedule and post-treatment
             care instructions

        Exclusion Criteria:

          -  Any laser treatment on neck and/or chest within 12 months

          -  Any topical treatment on neck and/or chest within 6 months

          -  Pregnant and/or breastfeeding

          -  Infection, dermatitis or a rash in the treatment area

          -  Suffering from significant concurrent illness, such as Diabetes Mellitus or pertinent
             neurological disorders

          -  History of seizure disorders due to light, fibromyalgia, connective tissue disease,
             vitiligo, psoriasis, pigmentary disorders, keloid scarring, hypertrophic scarring or
             abnormal wound healing

          -  History of immunosuppression/immune deficiency disorders or currently using
             immunosuppressive medications

          -  Having a known anticoagulative condition or taking anticoagulation medications

          -  History of diseases stimulated by heat, unless treatment is conducted following a
             prophylactic regimen

          -  Having undergone any surgery in the treatment area within 6 months of treatment (or
             more if skin has not healed completely)

          -  History of radiation to the head, neck and/or upper chest

          -  Undergoing systemic chemotherapy for the treatment of cancer

          -  Systemic use of isotretinoin (AccutaneÂ®) within 6 months

          -  Any use of gold therapy

          -  Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning
             during the study

          -  Current smoker or history of smoking within 12 months of study

          -  Participation in a study of another device or drug within 6 months

          -  As per the Investigator's discretion, any physical or mental condition which might
             make it unsafe for the subject to participate in study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Zel Skin and Laser Specialists</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55424</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2011</study_first_submitted>
  <study_first_submitted_qc>December 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2011</study_first_posted>
  <last_update_submitted>August 5, 2013</last_update_submitted>
  <last_update_submitted_qc>August 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>poikiloderma of Civatte</keyword>
  <keyword>red dyschromia</keyword>
  <keyword>brown dyschromia</keyword>
  <keyword>sun damage</keyword>
  <keyword>neck</keyword>
  <keyword>chest</keyword>
  <keyword>dyschromia</keyword>
  <keyword>pigmentation disorders</keyword>
  <keyword>erythema</keyword>
  <keyword>photosensitivity disorders</keyword>
  <keyword>sun exposure</keyword>
  <keyword>telangiectasia</keyword>
  <keyword>hyperpigmentation</keyword>
  <keyword>hypopigmentation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Telangiectasis</mesh_term>
    <mesh_term>Pigmentation Disorders</mesh_term>
    <mesh_term>Photosensitivity Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

